LEHI, UT, Nov. 7, 2023- Civica Inc. (Civica, Civica Rx) has been named a Best Place to Work by BioSpace, a popular digital hub for timely life science news and jobs. Civica is recognized in part for its emphasis on culture and innovation. “A talented team doing what is in the best interest of...
Author: Civica Rx
Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility
PETERSBURG, Va., Nov. 1, 2023 – Civica Inc. (Civica, Civica Rx) is proud to announce that pharmaceutical industry leader Bouwien Smits has joined Civica as the new Site Vice President and General Manager of the company’s new sterile injectable manufacturing facility. Smits has over 25 years of experience, including working with aseptic products and...
Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
Civica Inc. (Civica, Civica Rx) today announced that biopharma industry veteran Jay Benson has joined Civica as Chief Manufacturing and Supply Chain Officer. Benson replaces Russ Gall, who recently announced his retirement. Benson has 30 years of experience within the biopharmaceutical industry, including clinical and commercial manufacturing, global strategy development, and tech transfer and...
CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance and Savings
CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance. SortPak offers two packaging options to make it...
California Selects Civica Rx as Its Insulin Manufacturing Partner
LEHI, UTAH, March 18, 2023 – Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work. Once approved, Civica’s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and nationwide at...
Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
Civica, today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins. As previously announced, Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and sell the insulins at...
AmerisourceBergen Kicks Off Strategic Relationship with Civica
Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members. Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely....
Civica Inc. to Expand in Greater Richmond- Petersburg Region, Investing $27.8 Million for a New Testing Facility
Governor Glenn Youngkin today announced that non-profit Civica Inc. (Civica) will invest $27.8 million to establish a new laboratory testing facility at Meadowville Technology Park in Chesterfield County. The company will construct a 55,000-square-foot facility to support Civica’s Petersburg pharmaceutical manufacturing operation through quality testing and development of new products. The project will create 51 new...
National Essential Medicine Shortage Awareness Day
On this National Essential Medicine Shortage Awareness Day, September 8, we redouble our commitment to make quality essential medicines available and affordable to everyone. The shortage of medicines – including those used in emergency room care, the ICU, pain management, blood pressure control, and sedation – means unstable supplies for patient care and unpredictable...
CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings
CivicaScript, a public benefit company dedicated to bringing lower-cost generic medicines to U.S. consumers, today announced the availability of its first product: abiraterone acetate 250 mg tablets. Abiraterone is used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body. Starting today, CivicaScript will offer abiraterone...